Pediatrix Medical Group, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the Securities and Exchange Commission on October 29, 2026, reporting third-quarter net income of $46,991 thousand and nine-month net revenue of $1,465,353 thousand.

Key Highlights

  • Q3 2026 net revenue: $501,374 thousand, compared to $492,875 thousand in Q3 2025, according to the filing.
  • Q3 2026 net income: $46,991 thousand, or $0.59 per diluted share, versus $71,708 thousand, or $0.84 per diluted share, in the prior-year quarter.
  • Nine-month net income: $116,406 thousand, or $1.43 per diluted share, for the nine months ended September 30, 2026.
  • Share repurchases: The company repurchased common stock throughout the first three quarters of 2026, reducing shares outstanding from 82,976,110 at December 31, 2025 to 78,092,928 at September 30, 2026.
  • Total assets: $2,139,420 thousand as of September 30, 2026, down from $2,246,696 thousand at December 31, 2025.
  • Cash and cash equivalents: $311,916 thousand at September 30, 2026, compared to $375,241 thousand at December 31, 2025.
  • Shares outstanding: 78,124,716 shares of Common Stock as of October 27, 2026, as reported on the filing cover page.

Pediatrix Medical Group Results for the Nine Months Ended September 30, 2026

According to the filing, Pediatrix Medical Group (NYSE:MD) reported net revenue of $501,374 thousand for the three months ended September 30, 2026, an increase from $492,875 thousand in the same period of 2025. Income from operations for the quarter was $65,210 thousand, compared to $68,051 thousand in Q3 2025. The company reported income before income taxes of $64,992 thousand in Q3 2026, down from $87,778 thousand in Q3 2025, with the prior-year period including a net gain on investments in divested businesses of $20,906 thousand that did not recur in 2026.

For the nine months ended September 30, 2026, the filing disclosed net revenue of $1,465,353 thousand versus $1,420,078 thousand for the comparable 2025 period. Total operating expenses for the nine-month period were $1,301,564 thousand, compared to $1,260,059 thousand in the prior year. Practice salaries and benefits, the largest cost category, were $1,023,403 thousand for the nine months ended September 30, 2026. Transformational and restructuring related expenses for the nine-month period were $19,515 thousand, compared to $16,393 thousand in 2025.

On the balance sheet, the filing reported total shareholders' equity of $849,615 thousand at September 30, 2026, compared to $865,854 thousand at December 31, 2025. Long-term debt and finance lease liabilities, net, declined to $397,771 thousand from $570,532 thousand over the same period, while current portion of debt and finance lease liabilities, net, rose to $179,949 thousand from $26,806 thousand. The retained earnings (deficit) line moved from a deficit of $(83,152) thousand at December 31, 2025 to $0 at September 30, 2026, reflecting cumulative net income and the impact of share repurchases during the period.

What Was Disclosed

Pediatrix Medical Group filed its quarterly report covering the period ended September 30, 2026, disclosing Q3 net income of $46,991 thousand, nine-month net revenue of $1,465,353 thousand, a reduction in shares outstanding through repurchases, and updated balance sheet figures showing total assets of $2,139,420 thousand.